Please assess the completion status of the following clinical trial:

Trial Title: Trial to Evaluate the Efficacy of GSK Biologicals' Influenza Vaccine GSK2186877A in Adults 65 Year of Age and Older

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who the investigator believes that they can and will comply with the requirements of the protocol.~* A man or woman aged 65 years or older at the time of the vaccination.~* Written informed consent obtained from the subject.~* Subjects with residence status allowing free mixing with general community.~Exclusion Criteria:~* Bedridden subjects~* Previous vaccination against influenza since February 2008.~* Previous vaccination in the last three years with an investigational adjuvanted candidate seasonal or pandemic influenza vaccine.~* Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.~* Any contra-indication to intramuscular administration of the influenza vaccines.~* History of hypersensitivity to a previous dose of influenza vaccine.~* History of allergy or reactions likely to be exacerbated by any component of the vaccine including egg and chicken protein.~* Acute disease at the time of enrolment. Acute disease is defined as the presence of a moderate or severe illness with or without fever. All vaccines can be administered to persons with a minor illness such as diarrhoea, mild upper respiratory infection with or without low-grade febrile illness, i.e. Oral temperature \<37.5°C (99.5°F).

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- FluNG Group (Type: EXPERIMENTAL): subjects received 2 doses (1 dose per season) of FluNG vaccine during the Northern Hemisphere (NH) vaccination periods. One dose at Day 0 of the Year 1 and one dose at Day 0 of the Year 2 (= Day 365 Year 1).
- Fluarix Group (Type: ACTIVE_COMPARATOR): subjects received 2 doses (1 dose per season) of Fluarix™ vaccine during the Northern Hemisphere (NH) vaccination periods. One dose at Day 0 of the Year 1 and one dose at Day 0 of the Year 2 (= Day 365 Year 1).

Based on this trial design, predict the completion outcome and termination type (if applicable).